The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Recovery from mental illness: the guiding vision of the mental health service system in the 1990s
Anthony, W. A. (1993) · Psychosocial Rehabilitation Journal · doi:10.1037/h0095655 · Cited by 3,700
Users' guides to the medical literature
Guyatt, G. H. (1993) · JAMA · doi:10.1001/jama.270.17.2096 · Cited by 2,970
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
LEUCHT, S., KANE, J., KISSLING, W., HAMANN, J., ETSCHEL, E., & ENGEL, R. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.008 · Cited by 1,226
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
Full publication of results initially presented in abstracts.
Scherer, R. W., Langenberg, P., & von Elm, E. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000005.pub3 · Cited by 997
Song, F., Altman, D. G., Glenny, A.-M., & Deeks, J. J. (2003) · BMJ · doi:10.1136/bmj.326.7387.472 · Cited by 943
Treatment and prevention of mental disorders in low-income and middle-income countries
Patel, V., Araya, R., Chatterjee, S., Chisholm, D., Cohen, A., De Silva, M., Hosman, C., McGuire, H., Rojas, G., & van Ommeren, M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61240-9 · Cited by 930
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition
(2007) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.45859 · Cited by 737
Leucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13306-5 · Cited by 725
Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
Correll, C. U., Leucht, S., & Kane, J. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.414 · Cited by 709
Indirect comparisons of competing interventions
Glenny, A., Altman, D., Song, F., Sakarovitch, C., Deeks, J., D'Amico, R., Bradburn, M., & Eastwood, A. (2005) · Health Technology Assessment · doi:10.3310/hta9260 · Cited by 677
Stroup, T. S., McEvoy, J. P., Swartz, M. S., Byerly, M. J., Glick, I. D., Canive, J. M., McGee, M. F., Simpson, G. M., Stevens, M. C., & Lieberman, J. A. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006986 · Cited by 636
Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003) · BMJ · doi:10.1136/bmj.326.7400.1171 · Cited by 635
Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 631
Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Harvey, P. D., & Keefe, R. S. E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.176 · Cited by 620
Potkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M., Stock, E., Stringfellow, J., Ingenito, G., & Marder, S. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.681 · Cited by 591
Randomized Trials or Observational Tribulations?
Pocock, S. J., & Elbourne, D. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422511 · Cited by 550
Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial
Keefe, R. S. E., Bilder, R. M., Harvey, P. D., Davis, S. M., Palmer, B. W., Gold, J. M., Meltzer, H. Y., Green, M. F., Miller, D. D., Canive, J. M., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301072 · Cited by 472
Heres, S., Davis, J., Maino, K., Jetzinger, E., Kissling, W., & Leucht, S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.185 · Cited by 450
Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422
Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 407
Tiihonen, J., Walhbeck, K., Lönnqvist, J., Klaukka, T., Ioannidis, J. P. A., Volavka, J., & Haukka, J. (2006) · BMJ · doi:10.1136/bmj.38881.382755.2f · Cited by 385
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377
Lieberman, J. A., Phillips, M., Gu, H., Stroup, S., Zhang, P., Kong, L., Ji, Z., Koch, G., & Hamer, R. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300157 · Cited by 345
Conley, R. R., & Mahmoud, R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.5.765 · Cited by 334
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guide, Falkai, P., Wobrock, T., Lieberman, J., et al. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 331
Self-citationAtypical antipsychotics: new directions and new challenges in the treatment of schizophrenia
Kapur, S., & Remington, G. (2001) · Annual Review of Medicine · doi:10.1146/annurev.med.52.1.503 · Cited by 324
Kane (2003) · The Journal of Clinical Psychiatry · Cited by 323
Perlis, R. H., Perlis, C. S., Wu, Y., Hwang, C., Joseph, M., & Nierenberg, A. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1957 · Cited by 318
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, C. E., Severe, J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.611 · Cited by 306
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.782 · Cited by 306
Trial Registration at ClinicalTrials.gov between May and October 2005
Zarin, D. A., Tse, T., & Ide, N. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa053234 · Cited by 291
Swartz, M. S., Perkins, D. O., Stroup, T. S., Davis, S. M., Capuano, G., Rosenheck, R. A., Reimherr, F., McGee, M. F., Keefe, R. S. E., McEvoy, J. P., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.3.428 · Cited by 291
The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2006 Update
Moore, T. A., & Buchanan, R. W. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1115 · Cited by 288
Rosenheck, R. A., Leslie, D. L., Sindelar, J., Miller, E. A., Lin, H., Stroup, T. S., McEvoy, J., Davis, S. M., Keefe, R. S. E., Swartz, M., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2080 · Cited by 281
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guidelines for Schizophrenia, Falkai, P., Wobrock, T., Lieberman, J., et al. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 269
Self-citationTollefson, G. D., Sanger, T. M., Lu, Y., & Thieme, M. E. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.3.250 · Cited by 261
Davidson, M., Emsley, R., Kramer, M., Ford, L., Pan, G., Lim, P., & Eerdekens, M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.003 · Cited by 249
McQuade, R. D., Stock, E. G., Marcus, R. N., Jody, D. N., Abou-Gharbia, N., Vanveggel, S., Archibald, D., & Carson, W. H. (2004) · PubMed · Cited by 244
The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2003 Update
Miller, A. L., Hall, C. S., Buchanan, R. W., Buckley, P. F., Chiles, J. A., Conley, R. R., Crismon, M. L., Ereshefsky, L., Essock, S. M., Finnerty, M., et al. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0408 · Cited by 234
Lewis, S., Davies, L., Jones, P., Barnes, T., Murray, R., Kerwin, R., Taylor, D., Hayhurst, K., Markwick, A., Lloyd, H., et al. (2006) · Health Technology Assessment · doi:10.3310/hta10170 · Cited by 233
Reporting in randomized clinical trials improved after adoption of the CONSORT statement
Kane, R. L., Wang, J., & Garrard, J. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.06.016 · Cited by 227
Frances, R. J. (2007) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70411-0 · Cited by 220
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone
Green, M. F., Marder, S. R., Glynn, S. M., McGurk, S. R., Wirshing, W. C., Wirshing, D. A., Liberman, R. P., & Mintz, J. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01370-7 · Cited by 202
Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?
Tarsy, D., & Baldessarini, R. J. (2006) · Movement Disorders · doi:10.1002/mds.20823 · Cited by 200
What's atypical about atypical antipsychotic drugs?
Meltzer, H. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.09.010 · Cited by 196
Outcome selection bias in meta-analysis
Williamson, P. R., Gamble, C., Altman, D. G., & Hutton, J. L. (2005) · Statistical Methods in Medical Research · doi:10.1191/0962280205sm415oa · Cited by 188 · cited 1×
“, focusing on outcomes ‘favorable’ to the sponsor's product) (Heres et al., 2006; Williamson et al., 2005).”
BackgroundTreatment of Schizophrenia Negative Symptoms: Future Prospects
Erhart, S. M., Marder, S. R., & Carpenter, W. T. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj055 · Cited by 185
DESIGN AND REPORTING MODIFICATIONS IN INDUSTRY-SPONSORED COMPARATIVE PSYCHOPHARMACOLOGY TRIALS
SAFER, D. J. (2002) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-200209000-00002 · Cited by 180
McAlister, F. A., Laupacis, A., Wells, G. A., Sackett, D. L., & for the Evidence-Based Medicine Working Group (1999) · JAMA · doi:10.1001/jama.282.14.1371 · Cited by 177
Effectiveness of Switching Antipsychotic Medications
Essock, S. M., Covell, N. H., Davis, S. M., Stroup, T. S., Rosenheck, R. A., & Lieberman, J. A. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2090 · Cited by 172
Simpson, G. M., Glick, I. D., Weiden, P. J., Romano, S. J., & Siu, C. O. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1837 · Cited by 170
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
Peuskens, J., Bech, P., Möller, H.-J., Bale, R., Fleurot, O., & Rein, W. (1999) · Psychiatry Research · doi:10.1016/s0165-1781(99)00075-x · Cited by 170
Breier, A. F., Berg, P. H., Thakore, J. H., Naber, D., Gattaz, W. F., Cavazzoni, P. A., Walker, D. J., Roychowdhury, S. M., & Kane, J. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1879 · Cited by 156
Self-citationEPS Profiles: The Atypical Antipsychotics
Weiden, P. J. (2007) · Journal of Psychiatric Practice · doi:10.1097/00131746-200701000-00003 · Cited by 154
Seale, C. F., Chaplin, R., Lelliott, P. T., & Quirk, A. (2005) · Social Science & Medicine · doi:10.1016/j.socscimed.2005.11.002 · Cited by 148
Chrzanowski, W., Marcus, R. N., Torbeyns, A. F., Nyilas, M., & McQuade, R. D. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0564-3 · Cited by 146
Mullen, J., Jibson, M. D., & Sweitzer, D. E. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)89080-3 · Cited by 141
The case for long‐acting antipsychotic agents in the post‐CATIE era
Nasrallah, H. A. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00982.x · Cited by 136
Effectiveness of Switching to Ziprasidone for Stable but Symptomatic Outpatients With Schizophrenia
Weiden, P. J., Simpson, G. M., Potkin, S. G., & O’Sullivan, R. L. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0514 · Cited by 130
Another view of therapy for cognition in schizophrenia
Carpenter, W. T., & Gold, J. M. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01399-9 · Cited by 127
Management of the Negative Symptoms of Schizophrenia: New Treatment Options
M??ller, H.-J. (2003) · CNS Drugs · doi:10.2165/00023210-200317110-00003 · Cited by 125
Amisulpride vs. Risperidone in Chronic Schizophrenia Results of a 6-month Double-blind Study
Sechter, D. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00375-5 · Cited by 120
Montgomery, J. H., Byerly, M., Carmody, T. J., Li, B., Miller, D. R., Varghese, F. P., & Holland, R. (2004) · Controlled Clinical Trials · doi:10.1016/j.cct.2004.09.002 · Cited by 117
Davies, L. M., Lewis, S. W., Jones, P. B., Barnes, T. R. E., Gaughran, F., Hayhurst, K. P., Markwick, A., & Lloyd, H. M. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.106.028654 · Cited by 109
Tandon, R., Marcus, R. N., Stock, E. G., Riera, L. C., Kostic, D., Pans, M., McQuade, R. D., Nyilas, M., Iwamoto, T., & CRANDALL, D. T. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2005.12.857 · Cited by 107
Self-citationTuunainen, A., Wahlbeck, K., & Gilbody, S. M. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00212-2 · Cited by 103
The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial
Fleischhacker, W. W., Keet, I. P. M., & Kahn, R. S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.06.004 · Cited by 102
Self-citationJeste, D. V., Barak, Y., Madhusoodanan, S., Grossman, F., & Gharabawi, G. M. (2003) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200311000-00008 · Cited by 102
Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
Kane, J. M. (2006) · PubMed · Cited by 95
Potkin, S. G., Gharabawi, G. M., Greenspan, A. J., Mahmoud, R. A., Kosik‐Gonzalez, C., Rupnow, M. F. T., Bossie, C. A., Davidson, M., Burtea, V., & ZHU, Y. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.027 · Cited by 95
Lecrubier, Y., Quintin, P., Bouhassira, M., Perrin, E., & Lancrenon, S. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00887.x · Cited by 95
Meta-analysis: Methods, strengths, weaknesses, and political uses
Noble, J. H. (2006) · Journal of Laboratory and Clinical Medicine · doi:10.1016/j.lab.2005.08.006 · Cited by 94
Strategies for Maximizing Clinical Effectiveness in the Treatment of Schizophrenia
Tandon, R., Targum, S. D., Nasrallah, H. A., & ROSS, R. W. (2006) · Journal of Psychiatric Practice · doi:10.1097/00131746-200611000-00003 · Cited by 88
Self-citationExtrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome.
Tandon, R., & Jibson, M. D. (2002) · Annals of Clinical Psychiatry · doi:10.1023/a:1016811222688 · Cited by 86
Self-citationTenback, D. E., van Harten, P. N., Slooff, C. J., van Os, J., & SOHO Study Group (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.8.1438 · Cited by 86
Kinon, B. J., Lipkovich, I. A., Edwards, S. B., Adams, D. H., Ascher‐Svanum, H., & Siris, S. G. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000204137.82298.06 · Cited by 83
Comparative efficacy of antipsychotics in the treatment of schizophrenia: A critical assessment
Tandon, R., & WOLFGANGFLEISCHHACKER, W. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.025 · Cited by 81
Self-citationMortimer, A. M., Martin, S. D., Löo, H., & Peuskens, J. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200403000-00002 · Cited by 81
Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia
McCue, R. E., Waheed, R., Urcuyo, L., Orendain, G. C. M., Joseph, M. D., Charles, R., & Hasan, S. M. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.019307 · Cited by 81
Addington, D. E., Pantelis, C., Dineen, M., Benattia, I., & Romano, S. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1207 · Cited by 76
Clinical Trial-Based Cost-Effectiveness Analyses of Antipsychotic Use
Polsky, D. E., Doshi, J. A., Bauer, M. S., & Glick, H. A. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.12.2047 · Cited by 75
Kinon, B. J., Noordsy, D. L., Liu‐Seifert, H., Gulliver, A. H., Ascher‐Svanum, H., & Kollack‐Walker, S. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000236658.16286.25 · Cited by 73
Implications of the CATIE Trial on Treatment: Extrapyramidal Symptoms
Casey, D. E. (2006) · CNS Spectrums · doi:10.1017/s1092852900026651 · Cited by 69
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders.
(2003) · PubMed · Cited by 67
Comparison of Quetiapine and Risperidone in the Treatment of Schizophrenia
Zhong, K., Sweitzer, D. E., Hamer, R. M., & Lieberman, J. A. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0712 · Cited by 65
Olié, J., Spina, E., Murray, S., & Yang, R. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000182121.59296.70 · Cited by 64
Möller, H. (2000) · The World Journal of Biological Psychiatry · doi:10.3109/15622970009150570 · Cited by 58
Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations
Stroup, T. S., Alves, W. M., Hamer, R. M., & Lieberman, J. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1956 · Cited by 58
Kane, J. M. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.8.1316 · Cited by 58
Randomized controlled trials in schizophrenia: a critical perspective on the literature
Gilbody, S. M., Wahlbeck, K., & Adams, C. E. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.00242.x · Cited by 55
Martin, S. D., Löo, H., Peuskens, J., Thirumalai, S., Giudicelli, A., Fleurot, O., Rein, W., & for the SOLIANOL Study Group (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125001128 · Cited by 54
Martin, J. L. R., Pérez, V., Sacristán, M., & Álvarez, E. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2005.03.011 · Cited by 53
Hugenholtz, G. W. K., Heerdink, E. R., Stolker, J. J., Meijer, W. E. E., Egberts, T. C. G., & Nolen, W. A. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0606 · Cited by 53
Dundar, Y., Dodd, S. R., Dickson, R., Walley, T., Haycox, A. R., & Williamson, P. R. (2006) · Health Technology Assessment · doi:10.3310/hta10050 · Cited by 51
Azorin, J., Strub, N., & Loft, H. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000177020.26311.a7 · Cited by 47
Interpreting the Efficacy Findings in the CATIE Study: What Clinicians Should Know
Meltzer, H. Y., & Bobo, W. V. (2006) · CNS Spectrums · doi:10.1017/s109285290002664x · Cited by 42
Switching Between Second-Generation Antipsychotics: Why and How?
Edlinger, M., Baumgartner, S., ller, N. E.-F., Hummer, M., & Fleischhacker, W. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00003 · Cited by 35
Self-citationHoner, W. G., Thornton, A. E., Sherwood, M., MacEwan, G. W., Ehmann, T. S., Williams, R., Kopala, L. C., Procyshyn, R. M., & Barr, A. M. (2007) · CNS Drugs · doi:10.2165/00023210-200721090-00001 · Cited by 29
Consumer Perspectives on Quality of Care in the Treatment of Schizophrenia
Tunner, T. P., & Salzer, M. S. (2006) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-006-0050-6 · Cited by 28
Tollefson, G. D., Sanger, T. M., & Andersen, S. W. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)80375-1 · Cited by 28
Second-generation antipsychotics: reviewing the cost–effectiveness component of the CATIE trial
Rosenheck, R. A., Swartz, M. S., McEvoy, J. P., Stroup, T. S., Thomas, S., Keefe, R. S. E., Hsiao, J., & Lieberman, J. A. (2007) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.7.2.103 · Cited by 27
Tandon, R., & Jibson, M. D. (2005) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500510029192 · Cited by 21
Self-citationPublic Knowledge About Causes and Treatment for Schizophrenia
Schomerus, G., Borsche, J., Matschinger, H., & Angermeyer, M. C. (2006) · The Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000231428.98039.6c · Cited by 17
Garber, A. J., Johnson, D. L., Krauss, R. M., Marder, S. R., Meagher, J., McIntosh, B., & Newcomer, J. W. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0619 · Cited by 15
Optimizing pharmacotherapy of schizophrenia: Tools for the psychiatrist
Constantine, R. J., Richard, S. M., Surles, R. C., Medvedeff, D., Dewan, N. A., Mann, L., Williamson, J. M., & Tandon, R. (2006) · Current Psychosis & Therapeutics Reports · doi:10.1007/bf02629408 · Cited by 13
Self-citationAntipsychotic treatment of schizophrenia: Two steps forward, one step back
Tandon, R. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0029-3 · Cited by 5
Self-citationMéta-analyses ou méga-essais: un même niveau de preuves?
Mismetti, P., Cucherat, M., & Laporte, S. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2007.01.019 · Cited by 4
Schooler, N. R. (2007) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.1.1.2 · Cited by 3
Faut-il tenter de publier une étude qui ne conclut rien?
Texier, G., Meynard, J., Michel, R., Migliani, R., & Boutin, J. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2007.01.015 · Cited by 3
Do effectiveness studies tell us the real truth?
Möller, H. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701534935 · Cited by 3
Cited by
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Self-citationSykes, D. A., Moore, H., Stott, L., Holliday, N., Javitch, J. A., Lane, J. R., & Charlton, S. J. (2017) · Nature Communications · doi:10.1038/s41467-017-00716-z · Cited by 218
Ritsner, M. S., Miodownik, C., Ratner, Y., Shleifer, T., Mar, M., Pintov, L., & Lerner, V. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05324gre · Cited by 74
Rouillon, F., Chartier, F., & Gasquet, I. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.04.012 · Cited by 23
Metadata
- Authors
- Tandon, R., Belmaker, R. H., Gattaz, W. F., Lopez-Ibor, J. J., Okasha, A., Singh, B., Stein, D. J., Olie, J.-P., Fleischhacker, W. W., & Moeller, H.-J.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 100
- Issue
- 1-3
- Pages
- 20-38
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2027949421
- Cited by
- 276
- References
- 128
- FWCI
- 24.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.